These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 6231490)
1. Therapeutic failure of GABA agonist treatment in Huntington's disease. Waddington JL; Cross AJ Neurology; 1984 May; 34(5):702. PubMed ID: 6231490 [No Abstract] [Full Text] [Related]
2. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Shoulson I; Goldblatt D; Charlton M; Joynt RJ Trans Am Neurol Assoc; 1977; 102():124-5. PubMed ID: 150672 [No Abstract] [Full Text] [Related]
3. THIP treatment of Huntington's disease. Foster NL; Chase TN; Denaro A; Hare TA; Tamminga CA Neurology; 1983 May; 33(5):637-9. PubMed ID: 6221200 [TBL] [Abstract][Full Text] [Related]
4. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Shoulson I; Goldblatt D; Charlton M; Joynt RJ Ann Neurol; 1978 Sep; 4(3):279-84. PubMed ID: 152602 [TBL] [Abstract][Full Text] [Related]
5. GABA receptor agonists in intention myoclonus. Mondrup K; Dupont E; Braendgaard H Lancet; 1983 Dec 24-31; 2(8365-66):1490. PubMed ID: 6140573 [No Abstract] [Full Text] [Related]
6. GABA-agonist therapy for Alzheimer's disease. Mohr E; Bruno G; Foster N; Gillespie M; Cox C; Hare TA; Tamminga C; Fedio P; Chase TN Clin Neuropharmacol; 1986; 9(3):257-63. PubMed ID: 2872956 [TBL] [Abstract][Full Text] [Related]
7. GABA uptake inhibitors: relevance to antiepileptic drug research. Krogsgaard-Larsen P; Falch E; Larsson OM; Schousboe A Epilepsy Res; 1987 Mar; 1(2):77-93. PubMed ID: 2973980 [No Abstract] [Full Text] [Related]
8. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease. Durso R; Tamminga CA; Denaro A; Ruggeri S; Chase TN Neurology; 1983 Sep; 33(9):1229-32. PubMed ID: 6225034 [TBL] [Abstract][Full Text] [Related]
9. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Manyam BV; Katz L; Hare TA; Kaniefski K; Tremblay RD Ann Neurol; 1981 Jul; 10(1):35-7. PubMed ID: 6455963 [TBL] [Abstract][Full Text] [Related]
10. Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease. Hsu YT; Chang YG; Chang CP; Siew JJ; Chen HM; Tsai CH; Chern Y Mov Disord; 2017 Nov; 32(11):1600-1609. PubMed ID: 28782830 [TBL] [Abstract][Full Text] [Related]
11. Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. Manyam NV; Hare TA; Katz L Life Sci; 1980 Apr; 26(16):1303-8. PubMed ID: 6446011 [No Abstract] [Full Text] [Related]
18. Huntington's disease: modeling the gait disorder and proposing novel treatments. Banaie M; Sarbaz Y; Gharibzadeh S; Towhidkhah F J Theor Biol; 2008 Sep; 254(2):361-7. PubMed ID: 18621402 [TBL] [Abstract][Full Text] [Related]
19. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment? Lin F; Qin ZH J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512 [TBL] [Abstract][Full Text] [Related]
20. Broxaterol: a new beta2-adrenoceptor agonist for the treatment of reversible airways disease. Proceedings of the satellite symposium. Budapest, September 8, 1988. Respiration; 1989; 55 Suppl 2():1-44. PubMed ID: 2572034 [No Abstract] [Full Text] [Related] [Next] [New Search]